{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:52:47Z","timestamp":1781639567069,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Minimally invasive surgical therapies (MIST) for benign prostatic hyperplasia (BPH) have an advantage over other treatment options as they preserve sexual function and may be performed even in frail patients, often under local anesthesia. However, risks of clinical failure after such procedures may be considerably higher compared to standard modalities, making it important to assess the feasibility of repeat MIST in cases requiring retreatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A literature review was conducted in 2 databases, PubMed (Medline) and Google Scholar, with the following search query: (Aquablation OR PUL OR iTIND OR PAE OR Rezum) AND retreatment. The review only included articles that presented reoperation type (repeat MIST or conventional procedures) and its rate after MIST. Data was extracted and summarized in a tabular form.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Repeat MIST as a form of retreatment is technically feasible and has been reported for all modalities except iTIND (temporary implantable nitinol device) owing to the limited number of clinical trials. However, literature is sparse with detailed information about type of retreatment procedures and their outcomes, and reported rates of retreatment are low and variable: from 0% to 28.6% for PAE, 0\u20136.7% for Aquablation, 1\u20136.2% for Rezum, 2\u201320% for PUL. It is important to determine the exact cause of treatment failure. For persistent lower urinary tract symptoms (LUTS) attributable solely to BPH, such as incomplete treatment because of deviation from surgical protocols or untreated median lobe during the initial MIST, as well as BPH recurrence, repeat MIST may be appropriate if technically feasible. If any concomitant conditions (e.g., urethral stricture, bladder neck sclerosis, necrotic tissue after previous procedure) are suspected, and postoperative cystourethroscopy is indicated, combining diagnostic endoscopy with transurethral resection of the prostate (TURP) may be more reasonable. TURP is also preferred strategy in patients with severe LUTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rates of retreatment and need for ongoing therapy following MIST are generally low, and repeat MIST is feasible. Perhaps the best way to minimize re-intervention is to choose the appropriate primary treatment according to evidence based guidelines and to ensure proper surgical training. In case of retreatment, a surgeon should choose between repeat MIST or conventional approaches depending on the cause of relapse and patient\u2019s preferences (TURP or Aquablation for maximum durability and effectiveness; PUL, Rezum or PAE for minimal invasiveness, preservation of sexual function or reduction of operational risk).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06300-9","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:38:52Z","timestamp":1772217532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of clinical failure after minimally invasive surgical therapies (MIST) for BPH: repeat MIST versus resection, enucleation or ablation\u2014a narrative review from EAU endourology"],"prefix":"10.1007","volume":"44","author":[{"given":"Svetlana","family":"Bogatova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Morozov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Gauhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lifshitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Sukhanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Asali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Krupinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar K.","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. W.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Enikeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"7","key":"6300_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/iju.15454","volume":"31","author":"T Mitsui","year":"2024","unstructured":"Mitsui T et al (2024) Prevalence and impact on daily life of lower urinary tract symptoms in Japan: results of the 2023 Japan Community Health Survey (JaCS 2023). Int J Urol 31(7):747\u2013754. https:\/\/doi.org\/10.1111\/iju.15454","journal-title":"Int J Urol"},{"key":"6300_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jad.2024.08.205","volume":"367","author":"W Zhang","year":"2024","unstructured":"Zhang W et al (2024) LUTS\/BPH increases the risk of depressive symptoms among elderly adults: a 5-year longitudinal evidence from CHARLS. J Affect Disord 367:210\u2013218. https:\/\/doi.org\/10.1016\/j.jad.2024.08.205","journal-title":"J Affect Disord"},{"issue":"3","key":"6300_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1590\/S1677-5538.IBJU.2024.0039","volume":"50","author":"C Manfredi","year":"2024","unstructured":"Manfredi C, Napolitano L, Ditonno F et al (2024) Long-term functional outcomes and surgical retreatment after thulium laser enucleation of the prostate: a 10-year follow-up study. Int Braz J Urol 50(3):309\u2013318. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2024.0039","journal-title":"Int Braz J Urol"},{"issue":"2","key":"6300_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1089\/end.2019.0630","volume":"34","author":"A Morozov","year":"2020","unstructured":"Morozov A et al (2020) Retrospective assessment of endoscopic enucleation of prostate complications: a single-center experience of more than 1400 patients. J Endourol 34(2):192\u2013197. https:\/\/doi.org\/10.1089\/end.2019.0630","journal-title":"J Endourol"},{"issue":"7","key":"6300_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013656.pub2","volume":"7","author":"JV Franco","year":"2021","unstructured":"Franco JV, Jung JH, Imamura M et al (2021) Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database Syst Rev 7(7):CD013656. https:\/\/doi.org\/10.1002\/14651858.CD013656.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"6300_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1055\/s-0036-1586141","volume":"33","author":"H Yu","year":"2016","unstructured":"Yu H, Isaacson AJ, Burke CT (2016) Review of current literature for prostatic artery embolization. Semin Intervent Radiol 33(3):231\u2013235. https:\/\/doi.org\/10.1055\/s-0036-1586141","journal-title":"Semin Intervent Radiol"},{"issue":"6","key":"6300_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bju.13358","volume":"117","author":"P Gilling","year":"2016","unstructured":"Gilling P, Reuther R, Kahokehr A, Fraundorfer M (2016) Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 117(6):923\u2013929. https:\/\/doi.org\/10.1111\/bju.13358","journal-title":"BJU Int"},{"issue":"1","key":"6300_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1464-410X.2011.10342.x","volume":"108","author":"HH Woo","year":"2011","unstructured":"Woo HH et al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82\u201388. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10342.x","journal-title":"BJU Int"},{"key":"6300_CR9","doi-asserted-by":"publisher","unstructured":"Jones P, Rai BP, Aboumarzouk O, Somani BK (2016) UroLift: A new minimally-invasive treatment for benign prostatic hyperplasia. SAGE Publications Inc, Singapore https:\/\/doi.org\/10.1177\/1756287216671497","DOI":"10.1177\/1756287216671497"},{"issue":"2","key":"6300_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bju.12982","volume":"116","author":"F Porpiglia","year":"2015","unstructured":"Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D (Aug. 2015) Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int 116(2):278\u2013287. https:\/\/doi.org\/10.1111\/bju.12982","journal-title":"BJU Int"},{"issue":"5","key":"6300_CR11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.juro.2017.12.065","volume":"199","author":"P Gilling","year":"2018","unstructured":"Gilling P et al (2018) WATER: a double-blind, randomized, controlled trial of Aquablation\u00ae vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 199(5):1252\u20131261. https:\/\/doi.org\/10.1016\/j.juro.2017.12.065","journal-title":"J Urol"},{"key":"6300_CR12","unstructured":"Gilling P et al (2020) Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial"},{"issue":"3","key":"6300_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1148\/radiol.13122803","volume":"270","author":"YA Gao","year":"2014","unstructured":"Gao YA et al (2014) Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate-a prospective, randomized, and controlled clinical trial. Radiology 270(3):920\u2013928. https:\/\/doi.org\/10.1148\/radiol.13122803","journal-title":"Radiology"},{"issue":"1","key":"6300_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00270-015-1202-4","volume":"39","author":"FC Carnevale","year":"2016","unstructured":"Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M (2016) Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol 39(1):44\u201352. https:\/\/doi.org\/10.1007\/s00270-015-1202-4","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"6300_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14249","volume":"122","author":"AF Ray","year":"2018","unstructured":"Ray AF (2018) Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 122(2):270\u2013282. https:\/\/doi.org\/10.1111\/bju.14249","journal-title":"BJU Int"},{"issue":"3","key":"6300_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41391-023-00741-8","volume":"27","author":"S Kaplan","year":"2024","unstructured":"Kaplan S (2024) Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study. Prostate Cancer Prostatic Dis 27(3):485\u2013491. https:\/\/doi.org\/10.1038\/s41391-023-00741-8","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"6300_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.02.008","volume":"80","author":"D Abt","year":"2021","unstructured":"Abt D et al (2021) Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial[Formula presented]. Eur Urol 80(1):34\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2021.02.008","journal-title":"Eur Urol"},{"issue":"2","key":"6300_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.23736\/S0393-2249.16.02777-6","volume":"69","author":"L Cindolo","year":"2017","unstructured":"Cindolo L et al (2017) Bladder neck contracture after surgery for benign prostatic obstruction. Minerva Urol Nephrol 69(2):133\u2013143. https:\/\/doi.org\/10.23736\/S0393-2249.16.02777-6","journal-title":"Minerva Urol Nephrol"},{"issue":"4","key":"6300_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jvir.2012.12.019","volume":"24","author":"FC Carnevale","year":"2013","unstructured":"Carnevale FC et al (2013) Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol 24(4):535\u2013542. https:\/\/doi.org\/10.1016\/j.jvir.2012.12.019","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"6300_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jvir.2016.01.146","volume":"27","author":"AJ Isaacson","year":"2016","unstructured":"Isaacson AJ, Raynor MC, Yu H, Burke CT (2016) Prostatic artery embolization using Embosphere microspheres for prostates measuring 80\u2013150 cm3: early results from a US trial. J Vasc Interv Radiol 27(5):709\u2013714. https:\/\/doi.org\/10.1016\/j.jvir.2016.01.146","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"6300_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.euf.2023.12.001","volume":"10","author":"C Nedbal","year":"2024","unstructured":"Nedbal C, Castellani D, De Stefano V, Giulioni C, Nicoletti R, Pirola G, Teoh JY, Elterman D, Somani BK, Gauhar V (2024) Will aquablation be the new benchmark for robotic minimally invasive surgical treatment for benign prostatic hyperplasia? Eur Urol Focus 10(4):581\u2013593. https:\/\/doi.org\/10.1016\/j.euf.2023.12.001","journal-title":"Eur Urol Focus"},{"issue":"1","key":"6300_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MOU.0000000000000006","volume":"24","author":"A Chung","year":"2014","unstructured":"Chung A, Woo HH (2014) What\u2019s truly minimally invasive in benign prostatic hyperplasia surgery? Curr Opin Urol 24(1):36\u201341. https:\/\/doi.org\/10.1097\/MOU.0000000000000006","journal-title":"Curr Opin Urol"},{"key":"6300_CR23","doi-asserted-by":"publisher","unstructured":"Bach T, Gilling P, El Hajj A, Anderson P, Barber N (2020) First multi-center all-comers study for the aquablation procedure. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9020603","DOI":"10.3390\/jcm9020603"},{"key":"6300_CR24","unstructured":"Oumedjbeur K et al (2023) Aquablation versus TURP: 5-year outcomes of the WATER randomized clinical trial for prostate 50\u201380 mL"},{"issue":"11","key":"6300_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/bco2.430","volume":"5","author":"MB Berjaoui","year":"2024","unstructured":"Berjaoui MB, Nguyen DD, Almousa S, Daher K, Barber N, Bidair M, Gilling P, Anderson P, Zorn KC, Badlani G, Humphreys M, Kaplan S, Kaufman RP Jr, Elterman D, Desai M, Roehrborn C, Bhojani N (2024) WATER versus WATER II 5-year update: comparing aquablation therapy for benign prostatic hyperplasia in 30-80-cm3 and 80-150-cm3 prostates. BJUI Compass 5(11):1023\u20131033. https:\/\/doi.org\/10.1002\/bco2.430","journal-title":"BJUI Compass"},{"issue":"5S","key":"6300_CR26","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1097\/01.JU.0001008904.63948.3b.01","volume":"211","author":"D Gangwish","year":"2024","unstructured":"Gangwish D, Kuperus J, Palmateer G, Horning P, Zwaans B, Hafron J et al (2024) MP62-01\u2003water 3: aquablation outcomes for prostate volumes >150ml vs prostate volumes <150ml at a single community institution. J Urol 211(5S):e1020","journal-title":"J Urol"},{"issue":"1","key":"6300_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.urology.2011.10.021","volume":"79","author":"PT Chin","year":"2012","unstructured":"Chin PT (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5\u201311. https:\/\/doi.org\/10.1016\/j.urology.2011.10.021","journal-title":"Urology"},{"issue":"7","key":"6300_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00345-018-2494-1","volume":"37","author":"KD Sievert","year":"2019","unstructured":"Sievert KD et al (2019) Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 37(7):1353\u20131360. https:\/\/doi.org\/10.1007\/s00345-018-2494-1","journal-title":"World J Urol"},{"key":"6300_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2023.11.009","volume":"59","author":"JH Feiertag","year":"2023","unstructured":"Feiertag JH, Kane JA, Clark JY (2023) Incidence of surgical reintervention for benign prostatic hyperplasia following prostatic urethral lift, transurethral resection of the prostate, and photoselective vaporization of the prostate: a TriNetX analysis. Eur Urol Open Sci 59:63\u201370. https:\/\/doi.org\/10.1016\/j.euros.2023.11.009","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"6300_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.euf.2020.12.013","volume":"8","author":"CG Roehrborn","year":"2022","unstructured":"Roehrborn CG, Rukstalis DB (2022) Prostatic urethral lift versus medical therapy: examining the impact on sexual function in men with benign prostatic hyperplasia. Eur Urol Focus 8(1):217\u2013227. https:\/\/doi.org\/10.1016\/j.euf.2020.12.013","journal-title":"Eur Urol Focus"},{"key":"6300_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","volume":"126","author":"KT McVary","year":"2019","unstructured":"McVary KT, Rogers T, Roehrborn CG (2019) Rez\u016bm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 126:171\u2013179. https:\/\/doi.org\/10.1016\/j.urology.2018.12.041","journal-title":"Urology"},{"issue":"12","key":"6300_CR32","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1089\/end.2022.0385","volume":"36","author":"CP Chin","year":"2022","unstructured":"Chin CP, Garden EB, Ravivarapu KT, Shukla D, Omidele O, Levy M, Qian D, Araya JS, Valenzuela R, Reddy A, Marshall S, Motola J, Nobert C, Gupta M, Small AC, Kaplan SA, Palese MA (2022) Medium-term real-world outcomes of minimally invasive surgical therapies for benign prostatic hyperplasia: water vapor thermal therapy (Rezum) vs prostatic urethral lift (UroLift) in a high-volume urban academic center. J Endourol 36(12):1559\u20131566. https:\/\/doi.org\/10.1089\/end.2022.0385","journal-title":"J Endourol"},{"issue":"6","key":"6300_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.juro.2016.12.045","volume":"197","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG et al (2017) Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 197(6):1507\u20131516. https:\/\/doi.org\/10.1016\/j.juro.2016.12.045","journal-title":"J Urol"},{"issue":"5","key":"6300_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bju.15203","volume":"126","author":"MJ Johnston","year":"2020","unstructured":"Johnston MJ (2020) Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int 126(5):557\u2013558. https:\/\/doi.org\/10.1111\/bju.15203","journal-title":"BJU Int"},{"issue":"12","key":"6300_CR35","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00345-020-03140-z","volume":"38","author":"G Kadner","year":"2020","unstructured":"Kadner G et al (2020) Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol 38(12):3235\u20133244. https:\/\/doi.org\/10.1007\/s00345-020-03140-z","journal-title":"World J Urol"},{"key":"6300_CR36","doi-asserted-by":"publisher","DOI":"10.5534\/WJMH.190076","author":"A Srinivasan","year":"2019","unstructured":"Srinivasan A, Wang R (2019) An update on minimally invasive surgery for benign prostatic hyperplasia: techniques, risks, and efficacy. Korean Soc Sex Med Androl. https:\/\/doi.org\/10.5534\/WJMH.190076","journal-title":"Korean Soc Sex Med Androl"},{"issue":"5","key":"6300_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MOU.0000000000000912","volume":"31","author":"L Spivak","year":"2021","unstructured":"Spivak L, Morozov A, Shpikina A, Enikeev D, Rapoport L (2021) Postoperative medical treatment of lower urinary tract symptoms after benign prostatic hyperplasia surgery. Are we underestimating the problem? Curr Opin Urol 31(5):451\u2013455","journal-title":"Curr Opin Urol"},{"issue":"1","key":"6300_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jvir.2010.09.030","volume":"22","author":"JM Pisco","year":"2011","unstructured":"Pisco JM, Pinheiro LC, Bilhim T, Duarte M, Mendes JR, Oliveira AG (2011) Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol 22(1):11\u201319. https:\/\/doi.org\/10.1016\/j.jvir.2010.09.030","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"6300_CR39","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00330-012-2714-9","volume":"23","author":"JM Pisco","year":"2013","unstructured":"Pisco JM et al (2013) Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: Results of short- and mid-term follow-up. Eur Radiol 23(9):2561\u20132572. https:\/\/doi.org\/10.1007\/s00330-012-2714-9","journal-title":"Eur Radiol"},{"issue":"4","key":"6300_CR40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bju.12540","volume":"113","author":"AL Cantwell","year":"2014","unstructured":"Cantwell AL et al (2014) Multicentre prospective crossover study of the \u2018prostatic urethral lift\u2019 for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 113(4):615\u2013622. https:\/\/doi.org\/10.1111\/bju.12540","journal-title":"BJU Int"},{"issue":"5","key":"6300_CR41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.urology.2015.05.046","volume":"86","author":"C Dixon","year":"2015","unstructured":"Dixon C et al (2015) Efficacy and safety of Rez\u016bm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 86(5):1042\u20131047. https:\/\/doi.org\/10.1016\/j.urology.2015.05.046","journal-title":"Urology"},{"key":"6300_CR42","unstructured":"Desai M et al (2020) Aquablation for benign prostatic hyperplasia in large prostates (80\u2013150\u00a0cc): 2-year results"},{"key":"6300_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bju.13666","volume":"118","author":"D Rukstalis","year":"2016","unstructured":"Rukstalis D et al (2016) 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. BJU Int 118:14\u201322. https:\/\/doi.org\/10.1111\/bju.13666","journal-title":"BJU Int"},{"issue":"6","key":"6300_CR44","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/bju.14126","volume":"121","author":"MM Desai","year":"2018","unstructured":"Desai MM, Singh A, Abhishek S, Laddha A, Pandya H, Ashrafi AN, Ganpule AP, Roehrborn CG, Thomas AJ, Desai M, Sabnis RB (2018) Aquablation therapy for symptomatic benign prostatic hyperplasia: a single-centre experience in 47 patients. BJU Int 121(6):945\u2013951. https:\/\/doi.org\/10.1111\/bju.14126","journal-title":"BJU Int"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06300-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:02:43Z","timestamp":1781636563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06300-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6300"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06300-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}